Altheus Therapeutics Inc.
Expecting chemical synergy to improve ulcerative colitis
This article was originally published in Start Up
Executive Summary
If you can’t beat them, join them. Looks like the backers of Altheus Therapeutics Inc. see sound business sense in this homily: the start-up is working to create a potent new treatment for ulcerative colitis by combining N-acetylcysteine, an anti-inflammatory compound, with the aspirin derivative mesalamine, which for decades has been the front-line therapy for the condition.